company-header-background

Neuro9TM

Transfection

Nucleic Acid Transfection Kits for Primary Neurons

Overview

• 95% cell transfection efficiency
• No observed cytotoxicity
• Gene knockdown via siRNA expression
in vitro and in vivo applications
• Non-viral transfection

 

 

Applications:

• siRNA transfection for gene knockdown via RNAi both in vitro and in vivo

 

Top Right: Enriched (>90%) E18 primary rat cortical neurons treated at DIV12 with Neuro9 siRNA against HPRT. HPRT mRNA assayed by qPCR 48h post-treatment. *** P < 0.001

 

Middle Right: Enriched (>90%) E18 primary rat cortical neurons treated at DIV7 with Neuro9 siRNA against HPRT for 48 hours. Cell viability assayed using PrestoBlue.

 

Bottom Right: Primary rat neurons were treated at various stages of maturity with Neuro9 siRNA against PTEN. Neuro9 is well tolerated and can be applied at DIV ≥ 2. This flexibility opens doors to new experimental possibilities. *** P < 0.001

90% knockdown in 95% of Cells
90% Knockdown in 95% of Cells

No Observable Toxicity
No Observable Toxicity

Mediate Gene Expression as Early as DIV2
Mediate Gene Expression Early

Neuro9 in vitro cell culture and transfection
siRNA : > 95% Cellular Transfection Efficiency
Neuro9 In Vitro Cell Culture & Transfection

Images: Fluorescently labeled Neuro9 (red) is used to observe uptake by MAP2+ neurons (green).

Plot: Flow cytometry indicates Neuro9 uptake in >95% of cells


Neuro9 in vivo
siRNA : > 95% Transfection Efficiency
Neuro9 In Vivo Transfection
Neuro9 (red) was locally injected into rat somatosensory cortex. Brains were removed 5 days later, sliced and imaged. Calcein-AM dye (green) indicates neurons were alive when imaged. Western blots from samples 1mm from the injection site exhibit significant knockdown of target gene PTEN compared to “control” samples taken from the opposite hemisphere and samples treated with Luc siRNA.

Neuro9 Spark
Transfection Kits
Kit TypeEncapsulatesTreats (wells of 24 well plate)Catalogue
siRNA2 nmol (2x)50NWS0001
siRNA5 nmol100NWS0002

Neuro9 Benchtop
Transfection Kits
Kit TypeEncapsulatesTreats (wells of 24 well plate)Catalogue
siRNA0.5 mg15NWT0001
siRNA2 mg20NWT0002

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center

Publication - Summary

April 04, 2019

The Journal of Neuroscience

PTCD1 is required for mitochondrial oxidative-phosphorylation: possible genetic association with Alzheimer's disease

D. Fleck, L. Phu, E. Verschueren, T. Hinkle, M. Reichelt, T. Bhangale, B. Haley, Y. Wang, R. Graham, D.S. Kirkpatrick, M...

Read More

Publication - Summary

February 07, 2019

Nano Research

Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast can...

C. Zhang, X. Zhang, W. Zhao, C. Zeng, W. Li, B. Li, X. Luo, J. Li, J. Jiang, B. Deng, D.W. McComb, Y. Dong

Read More

Application Note

January 16, 2019

mRNA Lipid Nanoparticles: Robust low-volume production for screening high-value nanoparticle materials

Read More PDF

Publication - Summary

September 24, 2018

Nucleic Acid Therapeutics

MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct

R. Jain, JP. Frederick, EY. Huang, KE. Burke, DM. Mauger, EA. Andrianova, SJ. Farlow, S. Siddiqui, J. Pimentel, K. Cheun...

Read More

Poster

July 01, 2018

Robust low-volume production of nanoparticles for genetic manipulation of cells

Read More PDF

Publication - Summary

February 27, 2018

Cell Reports

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

J. Finn, A. Smith, M. Patel, L. Shaw, M. Youniss, J. Heteren, T. Dirstine, C. Ciullo, R. Lescarbeau, J. Seitzer, R. Shah...

Read More
Resource Center

Stay Informed

Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.

MENU
X